|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: VPS37C |
Gene summary for VPS37C |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | VPS37C | Gene ID | 55048 |
| Gene name | VPS37C subunit of ESCRT-I | |
| Gene Alias | VPS37C | |
| Cytomap | 11q12.2 | |
| Gene Type | protein-coding | GO ID | GO:0006508 | UniProtAcc | A5D8V6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55048 | VPS37C | LZE4T | Human | Esophagus | ESCC | 1.12e-02 | 1.19e-01 | 0.0811 |
| 55048 | VPS37C | LZE24T | Human | Esophagus | ESCC | 2.37e-21 | 5.70e-01 | 0.0596 |
| 55048 | VPS37C | P1T-E | Human | Esophagus | ESCC | 2.74e-02 | 1.41e-01 | 0.0875 |
| 55048 | VPS37C | P2T-E | Human | Esophagus | ESCC | 4.08e-09 | 1.56e-01 | 0.1177 |
| 55048 | VPS37C | P4T-E | Human | Esophagus | ESCC | 4.20e-06 | 1.86e-01 | 0.1323 |
| 55048 | VPS37C | P5T-E | Human | Esophagus | ESCC | 2.15e-10 | 1.22e-01 | 0.1327 |
| 55048 | VPS37C | P8T-E | Human | Esophagus | ESCC | 1.45e-17 | 4.35e-01 | 0.0889 |
| 55048 | VPS37C | P9T-E | Human | Esophagus | ESCC | 1.26e-02 | 1.12e-01 | 0.1131 |
| 55048 | VPS37C | P10T-E | Human | Esophagus | ESCC | 5.83e-13 | 1.13e-01 | 0.116 |
| 55048 | VPS37C | P11T-E | Human | Esophagus | ESCC | 6.39e-10 | 3.59e-01 | 0.1426 |
| 55048 | VPS37C | P12T-E | Human | Esophagus | ESCC | 1.16e-20 | 2.48e-01 | 0.1122 |
| 55048 | VPS37C | P15T-E | Human | Esophagus | ESCC | 4.08e-14 | 2.09e-01 | 0.1149 |
| 55048 | VPS37C | P16T-E | Human | Esophagus | ESCC | 1.28e-09 | 1.48e-01 | 0.1153 |
| 55048 | VPS37C | P17T-E | Human | Esophagus | ESCC | 1.73e-08 | 3.30e-01 | 0.1278 |
| 55048 | VPS37C | P19T-E | Human | Esophagus | ESCC | 1.78e-08 | 4.75e-01 | 0.1662 |
| 55048 | VPS37C | P20T-E | Human | Esophagus | ESCC | 9.12e-06 | 2.48e-01 | 0.1124 |
| 55048 | VPS37C | P21T-E | Human | Esophagus | ESCC | 1.53e-18 | 2.60e-01 | 0.1617 |
| 55048 | VPS37C | P22T-E | Human | Esophagus | ESCC | 3.81e-03 | 4.61e-02 | 0.1236 |
| 55048 | VPS37C | P23T-E | Human | Esophagus | ESCC | 7.46e-16 | 3.26e-01 | 0.108 |
| 55048 | VPS37C | P24T-E | Human | Esophagus | ESCC | 3.57e-08 | 1.61e-01 | 0.1287 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0072594110 | Esophagus | ESCC | establishment of protein localization to organelle | 311/8552 | 422/18723 | 3.02e-32 | 2.13e-29 | 311 |
| GO:0016032111 | Esophagus | ESCC | viral process | 301/8552 | 415/18723 | 3.34e-29 | 1.32e-26 | 301 |
| GO:001623617 | Esophagus | ESCC | macroautophagy | 216/8552 | 291/18723 | 1.94e-23 | 4.57e-21 | 216 |
| GO:0006605111 | Esophagus | ESCC | protein targeting | 229/8552 | 314/18723 | 4.93e-23 | 1.01e-20 | 229 |
| GO:0019058111 | Esophagus | ESCC | viral life cycle | 226/8552 | 317/18723 | 1.17e-20 | 1.76e-18 | 226 |
| GO:001605014 | Esophagus | ESCC | vesicle organization | 211/8552 | 300/18723 | 2.85e-18 | 2.87e-16 | 211 |
| GO:0090150110 | Esophagus | ESCC | establishment of protein localization to membrane | 182/8552 | 260/18723 | 1.27e-15 | 8.19e-14 | 182 |
| GO:000703417 | Esophagus | ESCC | vacuolar transport | 119/8552 | 157/18723 | 1.16e-14 | 6.30e-13 | 119 |
| GO:003625714 | Esophagus | ESCC | multivesicular body organization | 30/8552 | 31/18723 | 1.04e-09 | 2.50e-08 | 30 |
| GO:003625814 | Esophagus | ESCC | multivesicular body assembly | 29/8552 | 30/18723 | 2.21e-09 | 4.99e-08 | 29 |
| GO:00726659 | Esophagus | ESCC | protein localization to vacuole | 52/8552 | 67/18723 | 9.14e-08 | 1.52e-06 | 52 |
| GO:000703214 | Esophagus | ESCC | endosome organization | 61/8552 | 82/18723 | 1.13e-07 | 1.85e-06 | 61 |
| GO:001906815 | Esophagus | ESCC | virion assembly | 31/8552 | 35/18723 | 1.40e-07 | 2.25e-06 | 31 |
| GO:003970214 | Esophagus | ESCC | viral budding via host ESCRT complex | 20/8552 | 21/18723 | 1.83e-06 | 2.15e-05 | 20 |
| GO:00066238 | Esophagus | ESCC | protein targeting to vacuole | 31/8552 | 37/18723 | 1.95e-06 | 2.26e-05 | 31 |
| GO:004675514 | Esophagus | ESCC | viral budding | 23/8552 | 26/18723 | 6.82e-06 | 6.90e-05 | 23 |
| GO:00726668 | Esophagus | ESCC | establishment of protein localization to vacuole | 37/8552 | 49/18723 | 2.05e-05 | 1.78e-04 | 37 |
| GO:00066124 | Esophagus | ESCC | protein targeting to membrane | 83/8552 | 131/18723 | 3.31e-05 | 2.73e-04 | 83 |
| GO:00431623 | Esophagus | ESCC | ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathway | 19/8552 | 23/18723 | 3.12e-04 | 1.85e-03 | 19 |
| GO:007259418 | Oral cavity | OSCC | establishment of protein localization to organelle | 284/7305 | 422/18723 | 1.50e-32 | 1.35e-29 | 284 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa04144210 | Esophagus | ESCC | Endocytosis | 186/4205 | 251/8465 | 9.74e-16 | 4.66e-14 | 2.39e-14 | 186 |
| hsa0414437 | Esophagus | ESCC | Endocytosis | 186/4205 | 251/8465 | 9.74e-16 | 4.66e-14 | 2.39e-14 | 186 |
| hsa0414427 | Oral cavity | OSCC | Endocytosis | 174/3704 | 251/8465 | 9.42e-17 | 4.51e-15 | 2.29e-15 | 174 |
| hsa04144112 | Oral cavity | OSCC | Endocytosis | 174/3704 | 251/8465 | 9.42e-17 | 4.51e-15 | 2.29e-15 | 174 |
| hsa0414428 | Oral cavity | LP | Endocytosis | 121/2418 | 251/8465 | 1.89e-11 | 3.70e-10 | 2.38e-10 | 121 |
| hsa0414436 | Oral cavity | LP | Endocytosis | 121/2418 | 251/8465 | 1.89e-11 | 3.70e-10 | 2.38e-10 | 121 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| VPS37C | SNV | Missense_Mutation | c.842N>C | p.Gly281Ala | p.G281A | A5D8V6 | protein_coding | tolerated(0.2) | benign(0) | TCGA-AR-A1AJ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| VPS37C | SNV | Missense_Mutation | novel | c.319N>A | p.Glu107Lys | p.E107K | A5D8V6 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| VPS37C | SNV | Missense_Mutation | novel | c.304N>A | p.Asp102Asn | p.D102N | A5D8V6 | protein_coding | tolerated(0.46) | benign(0.409) | TCGA-C5-A7CK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| VPS37C | SNV | Missense_Mutation | novel | c.493N>A | p.Glu165Lys | p.E165K | A5D8V6 | protein_coding | tolerated(0.15) | probably_damaging(0.914) | TCGA-VS-A8EI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| VPS37C | SNV | Missense_Mutation | c.824C>T | p.Thr275Ile | p.T275I | A5D8V6 | protein_coding | deleterious(0.02) | benign(0) | TCGA-A6-6781-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | SD | |
| VPS37C | SNV | Missense_Mutation | novel | c.838N>C | p.Ser280Pro | p.S280P | A5D8V6 | protein_coding | tolerated(0.16) | benign(0.424) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| VPS37C | SNV | Missense_Mutation | rs746228096 | c.20A>C | p.Lys7Thr | p.K7T | A5D8V6 | protein_coding | tolerated(0.05) | possibly_damaging(0.812) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| VPS37C | SNV | Missense_Mutation | c.812N>A | p.Gly271Asp | p.G271D | A5D8V6 | protein_coding | deleterious(0) | possibly_damaging(0.567) | TCGA-AD-6964-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folfox | PD | |
| VPS37C | SNV | Missense_Mutation | c.473N>A | p.Arg158Lys | p.R158K | A5D8V6 | protein_coding | tolerated(0.17) | benign(0.005) | TCGA-AD-6964-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folfox | PD | |
| VPS37C | SNV | Missense_Mutation | novel | c.409N>C | p.Ser137Pro | p.S137P | A5D8V6 | protein_coding | tolerated(0.17) | benign(0.406) | TCGA-G4-6588-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |